RESEARCH MONOGRAPH · KDC-MN-071

Tianeptine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

73/100

Genuinely fascinating atypical antidepressant whose mu-opioid mechanism was hiding in plain sight for 30 years

Tianeptine is one of the most interesting molecules in psychopharmacology and the western pharma world basically ignored it for decades. Servier developed it in France in the 60s, it's been prescribed for major depression in France, Eastern Europe, Latin America, and parts of Asia for over 30 years, and the original mechanism story (serotonin reuptake enhancement, the opposite of an SSRI) turned out to be partly wrong.

Here's what we now know thanks to Gassaway, Javitch and others in 2014: tianeptine is a full agonist at mu-opioid receptors with surprisingly potent affinity (Ki around 380 nM), and the rapid antidepressant effect is mostly opioid-mediated. The serotonin story was a 30-year wrong-tree-barking situation. This matters because it puts tianeptine in the conversation alongside ketamine and psychedelics as fast-acting non-monoaminergic antidepressants, except tianeptine has 40+ years of real-world prescribing data behind it.

What we like is huge. The clinical efficacy data for depression and PTSD-anxiety comorbid presentations is genuinely strong, including head-to-head trials against SSRIs and fluoxetine. The fast onset (days, not weeks) is consistent with the opioid mechanism. And the basic pharmacology question of "how does a mu-opioid agonist used chronically produce antidepressant effects without classical opioid addiction in most patients" is one of the most interesting open questions in mood research.

What we dont like is what happened in the US gas-station-supplement market. Tianeptine free acid sold as "ZaZa" or "Tianna" got people hooked, the FDA issued warnings, multiple states have scheduled it, and the addiction-medicine literature now has a sad number of tianeptine dependence case reports. The problem is dose: therapeutic 12.5 mg sodium salt 3x/day vs. the multi-hundred-mg recreational dosing.

Sourcing is fine for the sodium salt at research grade, HPLC purity is achievable, and reputable vendors do clean chromatography. The free acid form has different bioavailability and stability and is what causes most of the dependence problems.

For studying atypical opioid-receptor antidepressant pharmacology, this is one of the most important tool compounds available. The dependence math matters at high doses but the underlying biology is genuinely promising.

Evidence: 75
Mechanism: 82
Reliability: 78
Safety: 55
Sourcing: 72
Value: 68
Signal: 80
Staying power: 75

Plain-language summary Intrigue 70 / 100

Tianeptine is a French-developed atypical antidepressant that, unusually, also activates the mu-opioid receptor. It has anxiolytic and mood-elevating effects but the opioid activity creates dependence and withdrawal at high doses. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Atypical antidepressant / mu-opioid agonist

A French-developed atypical antidepressant (Stablon) with full mu-opioid agonist activity at supratherapeutic doses; significant abuse and dependence liability.

Abstract

Tianeptine (Stablon, Coaxil; CAS 66981-73-5; molecular formula C21H25ClN2O4S; molecular weight 436.95) is a tricyclic-structurally-related atypical antidepressant developed by Servier in France in the 1980s and approved in Europe, Asia, and Latin America (not the United States) for major depressive disorder. The original mechanistic hypothesis was serotonin reuptake enhancement; subsequent work revealed that tianeptine is a full mu-opioid receptor agonist with potency approximately 10- to 20-fold lower than morphine. The opioid mechanism explains both the mood elevation and the substantial abuse and dependence liability that has emerged with chronic high-dose use. Reported research dose ranges in the literature are described in the source monograph. The FDA has issued warnings about tianeptine sold as a dietary supplement in the United States; multiple states have moved to schedule the compound. Investigators using tianeptine should be aware of the opioid pharmacology and dependence risk; the drug should not be regarded as a clean serotonergic antidepressant.

Mechanism of action

Full mu-opioid receptor agonist (10-20x weaker than morphine). Secondary glutamatergic effects in stress models.

Reported research dose ranges

12.5 mg (reported in the research literature). Abuse doses substantially higher.

References

Gassaway MM, et al. The atypical antidepressant tianeptine is a mu-opioid receptor agonist. Transl Psychiatry 2014.
FDA Drug Safety Communication on tianeptine, 2018.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-071

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Tianeptine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs